EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre randomised phase III, double blind, placebo controlled, parallel
group, outpatient study in patients diagnosed with hereditary pancreatitis and idiopathic
chronic pancreatitis.
The hypothesis to be tested is a 30% reduction in the number of days due to pancreatitis from
12.5 days per year to less than nine days per year under the treatment with magnesium or an
antioxidant cocktail called ANTOX.
A total of 288 patients will be randomised to one of three treatment groups in order to
compare pancreatic pain over a twelve month period.
Phase:
Phase 3
Details
Lead Sponsor:
University Medicine Greifswald
Treatments:
Beta Carotene Carotenoids N-Methylaspartate Selenium Vitamin E Vitamins